

- **Full Name:** Min Hwan Kim
 - **Current Position & Affiliation:** Clinical Assistant Professor, Yonsei University College of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- 2003.3 ~ 2009.2 M.D., Yonsei University College of Medicine, Seoul, Korea
- 2012.3 ~ 2014.2 M.S., Department of Medicine, Yonsei University College of Medicine
- 2014.3 ~ 2017.9 Ph.D. Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea

• Professional Experience:

- 2017.9 ~ 2018.2 PostDoc, Graduate School of Medical Science and Engineering, KAIST
- 2018.03~ 2019.2 Clinical Fellow, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- 2019.03~ 2020.02 Clinical Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- 2020.03~current Clinical Assistant Professor, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

• Professional Organizations:

- Member of KSMO, KCA, and KCSG
- Associate member of AACR
- Member of ASCO
- Member of KOGO

• Main Scientific Publications:

1. **Kim MH**, Kim GM, Ahn JM, Ryu WJ, Kim SG, Kim JH, Kim TY, Han HJ, Kim JY, Park HS, Park S, Park BW, Kim SI, Jeong J, Lee J, Paik S, Kim S, Jung KH, Cho EH, Sohn J. Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer. J Natl Cancer Inst. 2023 May 11:djad080. doi: 10.1093/jnci/djad080.
2. Kim CG*, **Kim MH***, Kim JH, Kim SG, Kim GM, Kim TY, Ryu WJ, Kim JY, Park HS, Park S, Cho YU, Park BW, Kim SI, Jeong J, Sohn J. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. Breast Cancer Res. 2023 Jan 12;25(1):4. doi: 10.1186/s13058-022-01601-4. *co-first authors

3. JG Yoon*, **MH Kim***, M Jang*, H Kim, HK Hwang, CM Kang, WJ Lee, B Kang, C Lee, MG Lee, HC Chung, HJ Choi, YN Park, Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses, Hepatology, 2021 Apr 21. doi: 10.1002/hep.31862 ***co-first authors**
4. Seo J*, **Kim MH***, Hong H, Cho H, Park S, Kim SK, Kim J. MK5 regulates YAP stability and is a molecular target in YAP-driven cancer, Cancer Res. 2019 Dec 15;79(24):6139-6152. doi: 10.1158/0008-5472.CAN-19-1339.cers. ***co-first authors**
5. **Kim MH**, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, Shin EC, Kim J. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018 Jan 30
6. **Kim MH**, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J, Actin Remodeling Confers BRAF Inhibitor Resistance to Melanoma Cells through YAP/TAZ Activation, The EMBO Journal 2016 Mar 1;35(5):462-78 (Journal Cover)